Literature DB >> 10188254

Genetic basis of macrolide and lincosamide resistance in Brachyspira (Serpulina) hyodysenteriae.

M Karlsson1, C Fellström, M U Heldtander, K E Johansson, A Franklin.   

Abstract

Macrolide antibiotic resistance is widespread among Brachyspira hyodysenteriae (formerly Serpulina hyodysenteriae) isolates. The genetic basis of macrolide and lincosamide resistance in B. hyodysenteriae was elucidated. Resistance to tylosin, erythromycin and clindamycin in B. hyodysenteriae was associated with an A-->T transversion mutation in the nucleotide position homologous with position 2058 of the Escherichia coli 23S rRNA gene. The nucleotide sequences of the peptidyl transferase region of the 23S rDNA from seven macrolide and lincosamide resistant and seven susceptible strains of Brachyspira spp. were determined. None of the susceptible strains were mutated whereas all the resistant strains had a mutation in position 2058. Susceptible strains became resistant in vitro after subculturing on agar containing 4 micrograms ml-1 of tylosin. Sequencing of these strains revealed an A-->G transition mutation in position 2058.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188254     DOI: 10.1111/j.1574-6968.1999.tb13476.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  24 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  A point mutation associated with bacterial macrolide resistance is present in both 23S rRNA genes of an erythromycin-resistant Treponema pallidum clinical isolate.

Authors:  L V Stamm; H L Bergen
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Ribosomal mutations in Arcanobacterium pyogenes confer a unique spectrum of macrolide resistance.

Authors:  B Helen Jost; Hien T Trinh; J Glenn Songer; Stephen J Billington
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A-->G.

Authors:  Peter Pfister; Natascia Corti; Sven Hobbie; Christian Bruell; Raz Zarivach; Ada Yonath; Erik C Böttger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-28       Impact factor: 11.205

5.  Trends towards lower antimicrobial susceptibility and characterization of acquired resistance among clinical isolates of Brachyspira hyodysenteriae in Spain.

Authors:  Álvaro Hidalgo; Ana Carvajal; Birte Vester; Märit Pringle; Germán Naharro; Pedro Rubio
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

6.  Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.

Authors:  A Tait-Kamradt; T Davies; M Cronan; M R Jacobs; P C Appelbaum; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 7.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

8.  Resistance to the peptidyl transferase inhibitor tiamulin caused by mutation of ribosomal protein l3.

Authors:  Jacob Bøsling; Susan M Poulsen; Birte Vester; Katherine S Long
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Collateral effects of antibiotics: carbadox and metronidazole induce VSH-1 and facilitate gene transfer among Brachyspira hyodysenteriae strains.

Authors:  Thaddeus B Stanton; Samuel B Humphrey; Vijay K Sharma; Richard L Zuerner
Journal:  Appl Environ Microbiol       Date:  2008-03-21       Impact factor: 4.792

Review 10.  Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics.

Authors:  Marilyn C Roberts
Journal:  Mol Biotechnol       Date:  2004-09       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.